Top Markets
#1 Orochi Network Orochi Network +75.87%
#2 Bitway Bitway +27.42%
#3 Audiera Audiera +26.10%
#4 RSK Infrastructure Framework RSK Infrastructure Framework +18.52%
#5 Zilliqa Zilliqa +15.74%
#6 SOON SOON +15.22%
#7 DeXe DeXe +14.77%
#8 Pharos Pharos +14.68%
#9 Taiko Taiko +14.38%
#10 Cap Cap +13.75%
Coin of the day
Orochi Network Orochi Network
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NVO
Pozycja w akcjach #72
Novo Nordisk A/S, a healthcare company, engages in the research, development,... Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Cena akcji
$50.93
Kapitalizacja rynkowa
$226.32B
Zmiana (1 dzień)
2.54%
Zmiana (1 rok)
-26.19%
Kraj
DK
Handel Novo Nordisk A/S (NVO)

Kategoria

Healthcare
Przychody dla Novo Nordisk A/S (NVO)
Przychody w Mar 2026 TTM: $52.05B
Według najnowszych raportów finansowych Novo Nordisk A/S, obecny przychód firmy (TTM) wynosi $52.05B. W roku 2024 firma osiągnęła przychód w wysokości $40.52B wzrost w porównaniu do przychodu z roku 2023, który wynosił $34.39B. Przychód to całkowita kwota dochodu generowana przez firmę ze sprzedaży towarów lub usług. W przeciwieństwie do zysku, nie są odliczane żadne koszty.
Historia przychodów firmy Novo Nordisk A/S od 2000 do 2026
Przychody na koniec każdego roku
Rok Przychody Zmień
2026 (TTM) $52.05B 11.49%
2025 $46.68B 15.22%
2024 $40.52B 17.82%
2023 $34.39B 35.02%
2022 $25.47B 18.29%
2021 $21.53B 3.33%
2020 $20.84B 13.79%
2019 $18.31B 6.63%
2018 $17.17B -4.59%
2017 $18.00B 13.46%
2016 $15.86B 0.88%
2015 $15.73B 8.89%
2014 $14.44B -6.28%
2013 $15.41B 11.69%
2012 $13.80B 19.42%
2011 $11.55B 6.01%
2010 $10.90B 10.52%
2009 $9.86B 15.53%
2008 $8.54B 3.65%
2007 $8.24B 20.44%
2006 $6.84B 28.15%
2005 $5.34B -0.14%
2004 $5.34B 18.51%
2003 $4.51B 27.01%
2002 $3.55B 25.45%
2001 $2.83B 9.05%
2000 $2.60B 0.00%
Przychody podobnych firm lub konkurentów
Firma Przychody Różnica w przychodach Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.26B -76.45%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.92B -71.33%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B -82.55%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $4.94B -90.50%
NL
Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
ALNY.US
 $4.29B -91.76%
US